Forte Biosciences (FBRX) Income from Continuing Operations (2016 - 2020)
Historic Income from Continuing Operations for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to -$9.4 million.
- Forte Biosciences' Income from Continuing Operations rose 4500.7% to -$9.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$55.8 million, marking a year-over-year decrease of 501.89%. This contributed to the annual value of -$63.5 million for FY2019, which is 2974.36% down from last year.
- Forte Biosciences' Income from Continuing Operations amounted to -$9.4 million in Q1 2020, which was up 4500.7% from -$10.6 million recorded in Q4 2019.
- In the past 5 years, Forte Biosciences' Income from Continuing Operations registered a high of -$383000.0 during Q3 2018, and its lowest value of -$19.6 million during Q4 2018.
- In the last 5 years, Forte Biosciences' Income from Continuing Operations had a median value of -$10.0 million in 2017 and averaged -$11.4 million.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 9615.19% in 2018, then crashed by 479164.49% in 2019.
- Over the past 5 years, Forte Biosciences' Income from Continuing Operations (Quarter) stood at -$8.5 million in 2016, then dropped by 28.08% to -$10.8 million in 2017, then crashed by 80.89% to -$19.6 million in 2018, then soared by 46.01% to -$10.6 million in 2019, then grew by 11.23% to -$9.4 million in 2020.
- Its Income from Continuing Operations stands at -$9.4 million for Q1 2020, versus -$10.6 million for Q4 2019 and -$18.7 million for Q3 2019.